VTVT - VTv Therapeutics: Unreasonably Cheap
Company Overview
vTv Therapeutics (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally-administered small molecule drug candidates. The firm has a pipeline of 7 clinical drug candidates, all in Phase 1 and 2. Azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts ("RAGE"), is the firm's lead asset. TTP399 is the firm's Type 2 Diabetes candidate, an orally administered, liver-selective glucokinase activator ("GKA"), which successfully completed a Phase 2b clinical trial in Type 2 diabetes (the "AGATA Study"). TTP273 is an another Type